soul trial oral semaglutide cardiovascular outcomes 2024 (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine SOUL: Oral Semaglutide Bests Usual
Pay in 4 interest-free payments of $6.03 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5








![[Season 2] Ep 3: Decoding GLP-1](https://i.ytimg.com/vi/cdpl4BpnBx8/hq720.jpg?sqp=-oaymwEhCK4FEIIDSFryq4qpAxMIARUAAAAAGAElAADIQj0AgKJD&rs=AOn4CLCRyjQqx66MN69i02jndKxQrO2omg)

















